New York State Psychiatric Institute has ALL human research trials suspended by ... trends now
View
comments
The New York State Psychiatric Institute has suspended all human research trials after a person taking part in a Parkinson's drug trial killed themselves.
A total of 417 research studies, with a budget of $86 million, were halted as federal regulators probe the center's safety protocols after a man who was part of the group trialling levodopa - a dopamine replacement agent - died.
Dr. Bret R. Rutherford, an associate professor of psychiatry at Columbia University was leading the study - which tested the drug for Parkinson’s disease.
He has since resigned from his prestigious position.
It is not clear when the suicide occurred, but the study - which received $736,579 in funding - was temporarily suspended by the National Institute of Mental Health in January 2022, first reported by Spectrum.
Dr. Bret R. Rutherford, an associate professor of psychiatry at Columbia University was leading the study, which tested the drug for Parkinson’s disease. He has since resigned from his prestigious position
Levodopa (pictured) is a dopamine replacement agent used in trial for the treatment of
